Information Journal Paper
APA:
Copy. (2017). MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. MOLECULAR CANCER THERAPEUTICS, 16(4), 739-751. SID. https://sid.ir/paper/738563/en
Vancouver:
Copy. MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. MOLECULAR CANCER THERAPEUTICS[Internet]. 2017;16(4):739-751. Available from: https://sid.ir/paper/738563/en
IEEE:
Copy, “MALAT1 is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2,” MOLECULAR CANCER THERAPEUTICS, vol. 16, no. 4, pp. 739–751, 2017, [Online]. Available: https://sid.ir/paper/738563/en